Yersinia pestis infection future or investigational therapies: Difference between revisions
No edit summary |
m (Changes made per Mahshid's request) |
||
| (10 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Yersinia pestis infection}} | {{Yersinia pestis infection}} | ||
{{CMG}}; {{AE}} {{JS}} | |||
==Overview== | |||
Current research aims to develop new and less invasive [[vaccines]] that protect from airborne infection of ''[[Yersinia pestis]]''. | |||
==Future and Investigational Therapies== | |||
Research studies are under way to improve the plague [[vaccine]]. The qualities searched in the new [[vaccine]] include:<ref name=Mandell>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref> | |||
* Protection from airborne [[infection]] | |||
* Inhaled administration | |||
A current potential [[vaccine]] is a recombinant type, expressing both V and F1 [[antigens]] of ''[[Yersinia pestis]]''. This [[vaccine]] appears to protect animals against airborne [[infection]] with ''[[Yersinia pestis]]''. Other options include:<ref name=Mandell>{{cite book | last = Mandell | first = Gerald | title = Mandell, Douglas, and Bennett's principles and practice of infectious diseases | publisher = Churchill Livingstone/Elsevier | location = Philadelphia, PA | year = 2010 | isbn = 0443068399 }}</ref> | |||
* Aerosolized [[monoclonal antibodies]] | |||
* Attenuated form of ''[[Yersinia pseudotuberculosis]]'' | |||
==References== | ==References== | ||
{{reflist|2}} | |||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Dermatology]] | [[Category:Dermatology]] | ||
[[Category:Pulmonology]] | [[Category:Pulmonology]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
Latest revision as of 19:31, 18 September 2017
|
Yersinia pestis infection Microchapters |
|
Differentiating Yersinia Pestis Infection from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Yersinia pestis infection future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Yersinia pestis infection future or investigational therapies |
|
FDA on Yersinia pestis infection future or investigational therapies |
|
CDC on Yersinia pestis infection future or investigational therapies |
|
Yersinia pestis infection future or investigational therapies in the news |
|
Blogs on Yersinia pestis infection future or investigational therapies |
|
Risk calculators and risk factors for Yersinia pestis infection future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: João André Alves Silva, M.D. [2]
Overview
Current research aims to develop new and less invasive vaccines that protect from airborne infection of Yersinia pestis.
Future and Investigational Therapies
Research studies are under way to improve the plague vaccine. The qualities searched in the new vaccine include:[1]
- Protection from airborne infection
- Inhaled administration
A current potential vaccine is a recombinant type, expressing both V and F1 antigens of Yersinia pestis. This vaccine appears to protect animals against airborne infection with Yersinia pestis. Other options include:[1]
- Aerosolized monoclonal antibodies
- Attenuated form of Yersinia pseudotuberculosis
References
- ↑ 1.0 1.1 Mandell, Gerald (2010). Mandell, Douglas, and Bennett's principles and practice of infectious diseases. Philadelphia, PA: Churchill Livingstone/Elsevier. ISBN 0443068399.